Trial · NCT07889726
"Anticipant"-TIPS After a First Portal-hypertension-related Complication in Cirrhosis
NCT07889726, Not applicable, Not yet recruiting, University Hospital, Toulouse
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. "Anticipant"-TIPS After a First Portal-hypertension-related Complication in Cirrhosis. Trials, record NCT07889726. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07889726
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- "Anticipant"-TIPS After a First Portal-hypertension-related Complication in Cirrhosis
- NCT number
- NCT07889726
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 266 participants, estimated
- Lead sponsor
- University Hospital, Toulouse
- Conditions
- Cirrhosis
- Interventions
- TIPS, Standard of Care (SOC)
- First posted
- 2026-10-22
- Last updated
- 2026-10-22
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Survival without further decompensation | 2 years | It will be defined as 1 large volume paracentesis \> 2 liters (one month after the randomization in case of ascites) or a new variceal bleeding or a new episode of overt hepatic encephalopathy (grade ≥ 2 of West-Heaven classification) or a new spontaneous bacterial peritonitis (neutrophils \> 250 / mm3 in ascites) or hepatorenal syndrome-acute kidney injury (according to the most recent definition) or jaundice (total bilirubin \> 50 μmol/l). It will be assessed during a 2-year follow-up period. |
| Secondary | Overall survival | 2 years | It will be assessed by measuring the overall survival, transplantation-free survival and liver-related death (composite criterion) during a 2-year follow up period. |
| Secondary | Incidence of new episode of grade 3 ascites | 1 month | It will be assessed by the apparition of new episode of grade 3 tense ascites defined as 1 large volume paracentesis \> 2 liters one month after the randomization. |
| Secondary | Number of large volume paracentesis (LVP) episodes per patient | 1 month | It will be assessed by the apparition of grade 3 tense ascites defined as 1 large volume paracentesis \> 2 liters one month after the randomization. |
| Secondary | Incidence of a new episode of variceal bleeding | 2 years | It will be assessed by the apparition of new episode of variceal bleeding according to Baveno V definition during a 2-year follow up period. |
| Secondary | Number of digestive bleeding episodes per patient | 2 years | It will be assessed by the apparition of new episode of variceal bleeding according to Baveno V definition during a 2-year follow up period. |
| Secondary | Incidence of a new episode of overt hepatic encephalopathy (Grade 2 - 4) | 2 years | It will be assessed by the apparition of new episode of overt hepatic encephalopathy defined as grade \> or = 2 according to the West-Haven classification during a 2-year follow up period. The West-Haven classification is a scale used to assess the severity of hepatic encephalopathy, consisting of 5 grades (0 corresponding to no clinical abnormalities and 4 to coma/unresponsive patient). |
| Secondary | Number of overt hepatic encephalopathy episodes per patient | 2 years | It will be assessed by the apparition of new episode of overt hepatic encephalopathy defined as grade \> or = 2 according to the West-Haven classification during a 2-year follow up period. |
| Secondary | Incidence of a new episode of severe overt hepatic encephalopathy (Grade 3 - 4) | 2 years | It will be assessed by the apparition of new episode of severe overt hepatic encephalopathy defined as grade \> or = 3 according to the West-Haven classification during a 2-year follow up period. |
| Secondary | Incidence of a new episode of jaundice | 2 years | It will be assessed by the apparition of new episode of jaundice defined as total bilirubin \> 50µmol/l during a 2-year follow up period. |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07889726
GET https://conductscience.org/api/trials/v1/NCT07889726/registered